% science
bn working braincells
1 strong vision
/ passion

icon_companyB

COMPANY

Dedicated to biosimilars: Cinfa Biotech.

Cinfa Biotech is the biosimilar company of Infarco group. We develop, manufacture and commercialise high-quality biosimilars. With headquarters in Pamplona, Spain, and offices in Munich, Germany, Europe is the center of our activities. Our vision is to achieve a premier position within the global biosimilar market as a fully integrated company, combining our specialist expertise in early- and late-stage biosimilar development and in global commercialisation of biosimilars. We are prepared to achieve our ambitious goals.

Shaping the future of biosimilars.

We're creating a pipeline of urgently needed biosimilars for oncology and inflammatory diseases that take into account the special requirements of patients, physicians, pharmacists, healthcare service providers and business partners. Based on proven science, quality, safety and efficacy, our biosimilars will widen the spectrum of therapeutic options with advantageous and affordable medications that reach more people and make valuable contributions to healthcare systems around the world. We are progressing quickly on our way to this goal: our first product candidate, a biosimilar version of Neulasta® (pegfilgrastim) has entered the clinical development phase.

A new way of thinking.

That is why Cinfa Biotech is different. A deep understanding of protein-based therapeutics and disease biology has enabled our team to define efficient biosimilar development programs, based on actual scientific and regulatory considerations. We develop and manufacture our products in Europe, strictly following highest European standards. Our team of renowned experts with decades of in-depth biosimilars experience, supported by a strong worldwide partner network, ensures that Cinfa Biotech's development gains further momentum.

Member of a strong family.

We are backed by our powerful parent company Infarco, which provides 50 years of experience in the development, manufacturing and commercialisation of pharmaceuticals. Infarco's first subsidiary, Laboratorios Cinfa, has become a leader in the Spanish pharmaceutical market, offering a broad portfolio of quality drugs. Cinfa Biotech has received an initial investment of EUR 70 million from Infarco to create a pipeline of biosimilars to address the growing need for affordable biologics therapies.

icon_teamB

TEAM

Ruediger Jankowsky

Ruediger Jankowsky, PhD Managing Director at Cinfa Biotech

Click here for CV
Braun-89fin_square

Dieter Braun, PhD Director Business Development at Cinfa Biotech.

Click here for CV
Karsten_Roth-840fin_square

Karsten Roth, PhD Director Clinical Operations at Cinfa Biotech.

Click here for CV

VISION

icon_mission

MISSION

Scientific advances for all patients.

Cinfa Biotech develops its biosimilars with an understanding of people’s genuine needs. This results in high-quality products that optimally fulfill the market’s needs.

Made in Europe. Successful worldwide.

European standards, know-how and product quality will be the keys to Cinfa Biotech’s success in the most important markets for biosimilars.

Affordable solutions for a broader market.

Our highly efficient development and production of biosimilars will create fair prices and enable more patients to benefit from medical progress.

Dedicated to biosimilars.

Based on the increasing need for affordable biologics therapies, Cinfa Biotech focuses exclusively on the development of safe, efficacious and affordable protein therapeutics.

PRODUCTS

Cinfa Biotech is creating a pipeline of high-quality biosimilars for several indications in oncology and inflammatory diseases. Our first product candidate is B12019, a biosimilar version of Neulasta® (pegfilgrastim) to treat chemotherapy-induced neutropenia. Pegfilgrastim is used to stimulate bone marrow to produce more neutrophils to decrease the incidence of infection in patients undergoing chemotherapy. B12019, a granulocyte colony-stimulating factor (G-CSF) receptor agonist, has entered clinical development in the fourth quarter of 2015. The clinical development program is based on scientific advice from the European Medicines Agency (EMA). Furthermore, the GMP production process has been established at commercial scale.

icon_partner

PARTNERING

Become our partner, let's design the market together.

Following our culture of deep history and expertise, we welcome ideas that have the potential to enhance our business. We have the structure, flexibility and entrepreneurial know-how to develop solutions tailored to the needs of our partners and customised for your markets. Our co-operations are guided by the experience that simple business solutions often prove to harbour the highest potential for future development. Professional partners with a strong footprint in their local market and disease expertise in oncology and inflammatory diseases are highly welcome to pioneer the market with us. We look forward to sharing your vision in detail.
Are you interested in collaborating with us? Please don’t hesitate to contact us.

icon_vacancies

JOIN US

Are you ready to pioneer the biosimilar business?

Unconventional products are created in an unconventionally pleasant working atmosphere at Cinfa Biotech. That’s why we’re looking for experts who are also distinguished by their superior “soft skills”: team players and passionate creators who appreciate working together in an atmosphere of mutual trust and candidness.
We look forward to meeting you!

Cinfa Biotech S.L.

Travesía de Roncesvalles, 1
E-31699 Olloki (Navarra)
Spain

Contact